• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

HepQuant SHUNT 可在临床代偿性慢性肝病的早期阶段检测门静脉高压。

HepQuant SHUNT Detects Portal Hypertension in Early Stages of Clinically Compensated Chronic Liver Disease.

机构信息

Section of Hepatology, Division of Gastroenterology and Hepatology, University of Colorado Anschutz Medical Campus, Aurora, Colorado.

National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland.

出版信息

Clin Gastroenterol Hepatol. 2022 Apr;20(4):e890-e894. doi: 10.1016/j.cgh.2021.04.030. Epub 2021 Apr 22.

DOI:10.1016/j.cgh.2021.04.030
PMID:33895359
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8531144/
Abstract

Physicians use portal pressure measurements in clinical practice and research but the methods are invasive, can cause complications, and are resource intensive. Herein we describe preliminary findings of the minimally invasive HepQuant-SHUNT test in the diagnosis of portal hypertension in precirrhotic and compensated cirrhotic patients.

摘要

医生在临床实践和研究中使用门脉压力测量，但这些方法具有侵袭性，可能导致并发症，且资源密集。在此，我们描述了微创 HepQuant-SHUNT 试验在诊断肝硬化前期和代偿期肝硬化患者门脉高压症中的初步发现。

相似文献

1
HepQuant SHUNT Detects Portal Hypertension in Early Stages of Clinically Compensated Chronic Liver Disease.HepQuant SHUNT 可在临床代偿性慢性肝病的早期阶段检测门静脉高压。
Clin Gastroenterol Hepatol. 2022 Apr;20(4):e890-e894. doi: 10.1016/j.cgh.2021.04.030. Epub 2021 Apr 22.
2
Hepatic improvement within 27 days of avenciguat treatment in Child-Pugh A cirrhosis detected by an oral cholate challenge test.阿维鲁单抗治疗 27 天内对 Child-Pugh A 级肝硬化的肝脏改善作用可通过口服胆酸挑战试验检测到。
Liver Transpl. 2024 Oct 1;30(10):982-990. doi: 10.1097/LVT.0000000000000420. Epub 2024 Jun 12.
3
Liver surgery in cirrhosis and portal hypertension.肝硬化和门静脉高压症的肝脏手术
World J Gastroenterol. 2016 Mar 7;22(9):2725-35. doi: 10.3748/wjg.v22.i9.2725.
4
The within-individual reproducibility of the disease severity index from the HepQuant SHUNT test of liver function and physiology.HepQuant SHUNT 肝功能和生理学检测疾病严重程度指数的个体内可重复性。
Transl Res. 2021 Jul;233:5-15. doi: 10.1016/j.trsl.2020.12.010. Epub 2021 Jan 2.
5
The usefulness of non-invasive liver stiffness measurements in predicting clinically significant portal hypertension in cirrhotic patients: Korean data.非侵入性肝硬度测量在预测肝硬化患者临床显著门静脉高压中的作用：韩国数据。
Clin Mol Hepatol. 2013 Dec;19(4):370-5. doi: 10.3350/cmh.2013.19.4.370. Epub 2013 Dec 28.
6
Predicting clinical decompensation in patients with cirrhosis using the Hepquant-SHUNT test.使用 Hepquant-SHUNT 测试预测肝硬化患者的临床失代偿。
Aliment Pharmacol Ther. 2021 Apr;53(8):928-938. doi: 10.1111/apt.16283. Epub 2021 Feb 8.
7
The impact of cirrhosis and portal hypertension on mortality following colorectal surgery: a nationwide, population-based study.肝硬化和门静脉高压对结直肠手术后死亡率的影响：一项基于全国人口的研究。
Dis Colon Rectum. 2009 Aug;52(8):1367-74. doi: 10.1007/DCR.0b013e3181a80dca.
8
Retrospective Study to Compare Selective Decongestive Devascularization and Gastrosplenic Shunt versus Splenectomy with Pericardial Devascularization for the Treatment of Patients with Esophagogastric Varices Due to Cirrhotic Portal Hypertension.比较选择性去充血性血管离断术联合胃脾分流术与脾切除加心包周围血管离断术治疗肝硬化门静脉高压症所致食管胃静脉曲张患者的回顾性研究。
Med Sci Monit. 2017 Jun 8;23:2788-2795. doi: 10.12659/msm.904660.
9
QT interval in patients with non-cirrhotic portal hypertension and in cirrhotic patients treated with transjugular intrahepatic porto-systemic shunt.非肝硬化门静脉高压患者及接受经颈静脉肝内门体分流术治疗的肝硬化患者的QT间期
J Hepatol. 2003 Apr;38(4):461-7. doi: 10.1016/s0168-8278(03)00057-6.
10
[Treatment of portal hypertension. Indications for and methods of portacaval shunt in the cirrhotic patient].[门静脉高压的治疗。肝硬化患者门腔分流术的适应证及方法]
Minerva Med. 1978 Apr 7;69(17):1167-70.

引用本文的文献

1
Cost-effectiveness of an oral cholate challenge test for the management of patients at risk for large esophageal varices.口服胆酸挑战试验用于管理大食管静脉曲张风险患者的成本效益分析。
PLoS One. 2024 Nov 22;19(11):e0313006. doi: 10.1371/journal.pone.0313006. eCollection 2024.
2
The Oral Cholate Challenge Test Quantifies Risk for Liver-Related Clinical Outcomes in Primary Sclerosing Cholangitis.口服胆酸盐激发试验可量化原发性硬化性胆管炎患者肝脏相关临床结局的风险。
Gastro Hep Adv. 2024 Jul 14;3(7):944-953. doi: 10.1016/j.gastha.2024.07.005. eCollection 2024.
3
Liver function and portal-systemic shunting quantified by the oral cholate challenge test and risk for large oesophageal varices.经口服胆酸挑战试验定量检测的肝功能和门体分流与发生大的食管静脉曲张风险。
Aliment Pharmacol Ther. 2024 Jul;60(2):246-256. doi: 10.1111/apt.18054. Epub 2024 May 22.
4
Dynamic Elevation of Aromatic Amino Acids in Hepatitis C Virus-Induced Cirrhosis After a Standard Meal.标准餐后丙型肝炎病毒相关性肝硬化患者芳香族氨基酸的动态升高。
Clin Transl Gastroenterol. 2024 Mar 1;15(3):e00666. doi: 10.14309/ctg.0000000000000666.
5
Found in translation-Fibrosis in metabolic dysfunction-associated steatohepatitis (MASH).翻译发现——代谢功能障碍相关脂肪性肝炎（MASH）中的纤维化
Sci Transl Med. 2023 Oct 4;15(716):eadi0759. doi: 10.1126/scitranslmed.adi0759.
6
Bibliometric-analysis visualization and review of non-invasive methods for monitoring and managing the portal hypertension.门静脉高压监测与管理的非侵入性方法的文献计量分析可视化与综述
Front Med (Lausanne). 2022 Sep 15;9:960316. doi: 10.3389/fmed.2022.960316. eCollection 2022.
7
Hepatic fibrosis 2022: Unmet needs and a blueprint for the future.2022 年肝脏纤维化：未满足的需求和未来蓝图。
Hepatology. 2022 Feb;75(2):473-488. doi: 10.1002/hep.32285. Epub 2022 Jan 11.

本文引用的文献

1
Predicting clinical decompensation in patients with cirrhosis using the Hepquant-SHUNT test.使用 Hepquant-SHUNT 测试预测肝硬化患者的临床失代偿。
Aliment Pharmacol Ther. 2021 Apr;53(8):928-938. doi: 10.1111/apt.16283. Epub 2021 Feb 8.
2
The within-individual reproducibility of the disease severity index from the HepQuant SHUNT test of liver function and physiology.HepQuant SHUNT 肝功能和生理学检测疾病严重程度指数的个体内可重复性。
Transl Res. 2021 Jul;233:5-15. doi: 10.1016/j.trsl.2020.12.010. Epub 2021 Jan 2.
3
Portal hypertension in primary biliary cholangitis: prevalence, natural history and histological correlates.原发性胆汁性胆管炎中的门静脉高压：患病率、自然史和组织学相关性。
Eur J Gastroenterol Hepatol. 2021 Dec 1;33(12):1595-1602. doi: 10.1097/MEG.0000000000002033.
4
The noninvasive diagnosis of esophageal varices and its application in clinical practice.食管静脉曲张的无创诊断及其在临床实践中的应用
Clin Res Hepatol Gastroenterol. 2018 Feb;42(1):6-16. doi: 10.1016/j.clinre.2017.07.006. Epub 2017 Sep 1.
5
Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension.病毒抑制对丙型肝炎肝硬化伴门静脉高压患者肝静脉压力梯度的影响。
J Viral Hepat. 2017 Oct;24(10):823-831. doi: 10.1111/jvh.12706. Epub 2017 Apr 10.
6
Noninvasive assessment of liver function.肝功能的无创评估。
Curr Opin Gastroenterol. 2015 May;31(3):199-208. doi: 10.1097/MOG.0000000000000167.
7
Portal hypertension and its complications.门静脉高压及其并发症。
Gastroenterology. 2008 May;134(6):1715-28. doi: 10.1053/j.gastro.2008.03.007.
8
Wedged hepatic venous pressure adequately reflects portal pressure in hepatitis C virus-related cirrhosis.肝静脉楔压能充分反映丙型肝炎病毒相关性肝硬化患者的门静脉压力。
Hepatology. 1999 Dec;30(6):1393-7. doi: 10.1002/hep.510300628.